-
1 Comment
BioGaia AB (publ) is currently in a long term uptrend where the price is trading 7.2% above its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 9.1.
BioGaia AB (publ)'s total revenue sank by 9.6% to $188M since the same quarter in the previous year.
Its net income has dropped by 26.8% to $38M since the same quarter in the previous year.
Finally, its free cash flow grew by 2215.2% to $53M since the same quarter in the previous year.
Based on the above factors, BioGaia AB (publ) gets an overall score of 3/5.
Sector | Healthcare |
---|---|
Industry | Drug Manufacturers - Specialty & Generic |
Exchange | F |
CurrencyCode | EUR |
ISIN | None |
Market Cap | 5B |
---|---|
PE Ratio | 35.62 |
Target Price | None |
Dividend Yield | 0.0% |
Beta | 0.78 |
BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates through three segments: Pediatrics, Adult Health, and Other. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of infantile colic and digestive health in children; antibiotic-associated and acute diarrhoea; gingivitis; periodontal disease; general health; Helicobacter pylori"the gastric ulcer bacterium; and low bone density. It offers its products under the BioGaia brand name. BioGaia AB (publ) was founded in 1990 and is headquartered in Stockholm, Sweden.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BGL.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025